PPT-Filgrastim in Neutropenia Post-Liver Transplant

By Ranya Razick PharmD 2021 Patient Presentation CC liverkidney transplant HPI EG is a 70yearold F with a significant history of NASH cirrhosis Pt presented to RUMC on 42 with altered mental status and abdominal distension PT had a liverkidney transplant on 47 complicated by a clotted portal vein and significant blood loss Postop EG had neutropenia and hypothermia On 49 she underwent an abdominal washout . U. nusual Cases. . . . Ahmet. . Gurakar. , MD. . . Johns Hopkins School of Medicine. Medical Director, Liver Transplant Program . Jeff Halldorson M.D.. Associate Professor. Transplant Surgery. UCSD Department of Surgery. Liver Allocation Proceeds by “Sickest First” Principle. Acute “Fulminant” Liver Failure (Expected Lifespan <7 days without Transplantation). Bertus Eksteen. Aspen Woods Clinic and University of Calgary . Canada. Important considerations. Predicting timing to list for transplant. Risk of death without transplant. Year 1 liver transplant mortality 10-12%. Donna . Ferchill. , RN, BSN . Clinical Nurse Manager, . Liver Transplant Program, Cleveland Clinic. Julie . Plescia. , RN, BSN, CCTC . Manager of Organ Services,. Lifebanc. Objectives:. What is a MELD score?. Myelosuppression. Dr. Khaled Abulkhair, PhD. Medical Oncology SCE, royal College. Ass. Professor of Clinical Oncology, Mansoura University. Infections in cancer patients. Outline. Introduction. Definitions. Jennifer Guy, MD, MAS. Director, Liver Cancer Program. Transplant . Hepatologist. California Pacific Medical Center. 1. Liver Transplant Questions. Who needs a liver transplant for PSC?. What is a liver transplant?. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology . 2015;148:100-7. Treatment Naïve and Treatment Experienced Liver Transplantation Source: Curry MP, et Professor of Pediatrics, Harvard Medical School. Director, Bone Marrow Failure and Myelodysplastic Syndrome Programs. Jim Connelly, MD. Assistant Professor of Pediatrics, Vanderbilt University Medical Center. ID : . DB09560 . Indication. . :. Patients with Cancer Receiving . Myelosuppressive. Chemotherapy: to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with . Milan Kinkhabwala, MD. Professor of Surgery . Director of Abdominal Transplantation. Montefiore Einstein Center for Cancer Care. History of Transplant. Understanding of . Alloimmunity. : Medawar et al 1950’s. 23 European Review for Medical and Pharmacological Sciences2017; 21 (1 Suppl): 23-36 F.R. PONZIANI1, S. BHOORI2, M. POMPILI1, M.A. ZOCCO1, M. BIOLATO1, G. MARRONE1, A. GASBARRINI1, V. MAZZAFERRO2, A. GRANIX (tbo - filgrastim), NIVESTYM (filgrastim - aafi), RELEUKO (filgrastim - ayow), ZARXIO (filgrastim - sndz) The biosimilar medications in bold are the preferred products for claims adjudicated Hematopoietic Agents : Granulocyte Colony Stimulating Factor(GCSF)Medical olicy o. EffectiveDateJuly , 2019 Drug Medical Necessity filgrastim (Neupogen) filgrastimaafi (Nivestym)filgrastimsndz (Zarxio Download PDF Fatty Liver Remedy™ eBook by Layla Jeffrey - a comprehensive guide designed to address and alleviate the symptoms of fatty liver disease through natural and lifestyle-based approaches.